Highest-materiality recent filing
PetVivo raises $1M via unit offering with warrants; $1.5M option available
Raised $1M from 1.25M units at $0.80/unit; each unit = 1 restricted common share + 1 warrant at $1.10/strike, 3-year term.
PetVivo raises $1M in private placement, secures option for additional $1.5M
Issued 1,250,000 restricted common shares and warrants at $0.80/unit for $1M; $400K received Mar 13, 2026.
PetVivo converts $2.02M debt into 3.67M shares via note conversion agreements
Four shareholders converted $2,018,155 aggregate debt (principal $1.85M + interest $168,155) into 3,669,806 restricted shares.
PetVivo receives $3M from partial exercise of Series B convertible preferred stock purchase option
Received $3,000,000 from partial exercise of Purchase Option; total proceeds to date $4,000,000 out of $5,000,000 offering.
Received $200,000 on May 6, 2025 from partial exercise of Purchase Option under March 26 Subscription Agreement.
PetVivo raises $5M via Series B Convertible Preferred Stock; initial $600K funded
$5M Series B Convertible Preferred offering at $1.00/share; $600K initial, option for additional $4.4M.
PetVivo raises $5M in Series B convertible preferred stock financing
Initial $600K received; investor may purchase remaining $4.4M by May 27, 2025.
PetVivo signs exclusive license for VetStem's PrecisePRP canine and equine products
Upfront license fee of $500,000; milestone payments up to $500,000 in $250,000 increments.
PetVivo Chairman James Martin passes away on September 28, 2024
James Martin, Chairman of the Board, died peacefully on September 28, 2024.
PetVivo Holdings delisted from Nasdaq; securities to trade on OTCQB
Nasdaq filed Form 25 on Sept 6, 2024 to delist PETV and PETVW due to noncompliance with Listing Rule 5550(b).
PetVivo to delist from Nasdaq, begin trading on OTCQB on July 29
Nasdaq Board declined to review delisting decision on July 25, 2024; company will not appeal to SEC.
PetVivo raises $1.21M via private placement of Series A Preferred and warrants at $0.40/unit
Raised $1,210,000 by selling 3,025,000 units at $0.40/unit to 3 accredited investors.
PetVivo FY2024 revenue up 6% to $969K; net loss widens to $11.0M; FY2025 guidance $1.5-$2.0M
Revenue $969K (+6% YoY); gross margin 76.3% (+40 bps).
PetVivo receives Nasdaq delisting notice; trading suspended April 9; appeals ongoing
Nasdaq Panel determined PetVivo failed to comply with $2.5M stockholders' equity rule by April 1, 2024.
PetVivo appoints Garry Lowenthal as CFO with $200k salary and 90,000 RSUs
Mr. Lowenthal appointed CFO effective March 8, 2024; base salary $200,000 paid to his holding company.
PetVivo Q3 revenue up 17% YoY to $596K; net loss narrows to $1.75M
Revenue $595,891 vs $510,109 YoY; new Covetrus distribution contributed $106K, MWI sales $440K.
PetVivo raises $1.25M in private placement of units at $0.90/unit
Sold 1,386,469 units to 13 accredited investors at $0.90 per unit.
PetVivo CFO Robert Folkes resigns effective Feb 2, 2024; will assist during transition
Robert J. Folkes resigns as CFO, effective February 2, 2024.
By eliminating the position of COO, the Board also terminated the employment of Randall A. Meyer, effective immediately;
On September 28, 2024, James Martin, a director and Chairman of the Board of PetVivo Holdings, Inc. (the “Company”), peacefully passed away.
Effective as of September 25, 2024, the Board of Directors of PetVivo Holdings, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Mike Eldred as a member of the Board to fill the vacancy created by the increase in size of the Board.
led by Garry Lowenthal, the Company’s new Chief Financial Officer.
On March 8, 2024, PetVivo Holdings, Inc. (the “Company”) appointed Garry Lowenthal to serve as the Company’s Chief Financial Officer.
he will be resigning as Chief Financial Officer (“CFO”) of the Company, effective as of February 2, 2024.
Max materiality 0.90 · Median 0.50 · Most common event other_material